31 Oct 2026
Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
Author: admintech | Filed under: Press ReleaseSHANGHAI, Oct. 31, 2026 /PRNewswire/ — Shanghai Zhimeng Biopharma, Inc. ( “Zhimeng Biopharma”) announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully…